Melanoma primario de cuello uterino: Reporte de caso
DOI:
https://doi.org/10.35509/01239015.104Palabras clave:
Cuello del útero, Melanoma maligno, Inmunoterapia, Diagnóstico, Hemorragia uterina, InmunohistoquímicaResumen
El melanoma primario de mucosas representa el 1% de todos los cánceres. Su localización en cuello uterino es rara y existen menos de 100 casos reportados en la literatura hasta la fecha. Los datos son limitados en cuanto su estadificación y tratamiento y su pronóstico es malo con tasas de supervivencia del 10% a 5 años. Se presenta el caso clínico de una paciente de 82 años con sangrado vaginal, con evidencia de una lesión melanótica en cuello uterino, la biopsia de la lesión reportó compromiso por tumor maligno pobremente diferenciado, con inmuno perfil que confirma melanoma maligno. Los estudios de extensión no mostraron enfermedad metastásica a distancia, se presentó el caso en junta multidisciplinaria de ginecología oncológica por lo que se indicó tratamiento con radioterapia pélvica externa exclusiva con intención paliativa para control de síntomas, teniendo en cuenta: la edad, las comorbilidades y el estado funcional ECOG (Eastern Cooperative Oncology Group) 3; luego de 10 meses de seguimiento la paciente falleció.
Referencias bibliográficas
Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56(5):828-34. https://doi.org/10.1016/j.jaad.2006.06.017
Lim KH, Tay SK, Ng AXH, Mantoo S. Primary Melanoma of the Uterine Cervix: A Case Report, with Key Points on Recognition and Pathological Diagnosis. J Low Genit Tract Dis. 2017;21(1):e1-4. https://doi.org/10.1097/LGT.0000000000000264
Pusceddu S, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M, Buzzoni R. A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer. Crit Rev Oncol Hematol. 2012;81(2):185-95. https://doi.org/10.1016/j.critrevonc.2011.03.008
McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000-7. https://doi.org/10.1002/cncr.20866
Zamiati S, Sahraoui S, Jabri L, Louahlia S, Sqalli S, Kahlain A. Mélanome malin primitif du col utérin: À propos d’un cas avec revue de la littérature. Gynecol Obstet Fertil. 2001;29(5):381-5. https://doi.org/10.1016/S1297-9589(01)00148-5
Myriokefalitaki E, Babbel B, Smith M, Ahmed AS. Primary malignant melanoma of uterine cervix FIGO IIa1: A case report with 40months ongoing survival and literature review. Gynecol Oncol Reports. 2013;5:52-4. https://doi.org/10.1016/j.gynor.2013.04.004
Deshpande AH, Munshi MM. Primary malignant melanoma of the uterine cervix: Report of a case diagnosed by cervical scrape cytology and review of the literature. Diagn Cytopathol. 2001;25(2):108-11. https://doi.org/10.1002/dc.2014
Cetinkaya K, Benzer E, Dervisoglu H. Primary mucosal malignant melanoma of the cervix: Case report and review of the literature. Tumori. 2015;101(5):e147-50. https://doi.org/10.5301/tj.5000304
Jin B, Goldsmith A, Budev H, Al-Abbadi M. Primary melanoma of the uterine cervix after supracervical hysterectomy: A case report. Acta Cytol. 2007;51(1):86-8. https://doi.org/10.1159/000325690
Gupta S, Sodhani P, Jain S. Primary malignant melanoma of uterine cervix: A rare entity diagnosed on fine needle aspiration cytology - Report of a case. Cytopathology. 2003;14(3):153-6. https://doi.org/10.1046/j.1365-2303.2003.00014.x
Samper AM. Melanoma de alto riesgo reestadificado con F-18-FDG-PET/CT. Rev Colomb Cancerol. 2014;18(4):202-5. https://doi.org/10.1016/j.rccan.2014.04.004
Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol. 2008;9(10):973-81. https://doi.org/10.1016/S1470-2045(08)70254-7
Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97(1):98-103. https://doi.org/10.1002/bjs.6784
Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P. Embryonal rhabdomyosarcoma of the uterine cervix: Case report and review of the literature. Gynecol Oncol. 2003;91(2):452-5. https://doi.org/10.1016/S0090-8258(03)00539-0
Hutchinson F, Cancer S, Alliance C. Treatment of Metastatic Melanoma : An Overview - Cancer Network Treatment of Metastatic Melanoma : An Overview Treatment of Metastatic Melanoma : An Overview - Cancer Network. Network. 2010;23(6):1-7.
Oliva ICG, Alqusairi R. Immunotherapy for Melanoma. In: Naing A, Hajjar J (Editiors). Immunotherapy. Second Edition. Springer; 2018. p. 43-63. https://doi.org/10.1007/978-3-030-02505-2_2
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-16. https://doi.org/10.1200/JCO.1999.17.7.2105
Wei SC, Levine JH, Cogdill AP, Zhao Y, Andrews MC, Sharma P, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2018;170(6):1120-33. https://doi.org/10.1016/j.cell.2017.07.024
Sosman JA, Haanen JB, Gonzalez R, Robert C, Ph D, Schadendorf D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. https://doi.org/10.1056/NEJMoa1003466
Lin GG, Scott JG. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24-33. https://doi.org/10.1016/j.molmed.2014.10.009
Hodi S, Chesney J, Pavlick AC, Robert C, Grossmann KF, Mcdermott DF, et al. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol. 2016;17(11):1558-68. https://doi.org/10.1016/S1470-2045(16)30366-7
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-62. https://doi.org/10.1016/S0140-6736(17)31601-X
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2013;367(18):1694-703. https://doi.org/10.1056/NEJMoa1210093
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-90. https://doi.org/10.1200/JCO.2012.47.7836
Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, et al. Update on primary mucosal melanoma. J Am Acad Dermatol. 2014;71(2):366-75. https://doi.org/10.1016/j.jaad.2014.03.031
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Todos los derechos reservados.
